Xconomy: Boston News, Articles and Opinions

Results for “”

Entry	Author	Date	Location
Xconomy Awards Boston 2019 Honors Best in Life Sciences: Slideshow	Jeff Bauter Engel	10/23/19	Boston
Biogen Reverses Course on Alzheimer’s Drug Analysis, Plans FDA Filing	Sarah de Crescenzo	10/22/19	Boston
Vertex Stock Up on Quick FDA OK For 3-Drug Cystic Fibrosis Therapy	Sarah de Crescenzo	10/22/19	Boston
Backed by $50M, Verseau Launches to Reprogram Immune Cells Against Cancer	Frank Vinluan	10/21/19	Boston
Enzyvant Adds Compass’s Jeb Ledell as Its Chief Operating Officer	Sarah de Crescenzo	10/18/19	Boston
Pyxis Oncology Taps MedImmune’s Herbst as Chief Scientific Officer	Sarah de Crescenzo	10/18/19	Boston
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More	Frank Vinluan	10/18/19	National
Healx Bags $56M to Advance Affordable, AI-Based Orphan Drugs	Mike Ward	10/17/19	National
Nuance & Microsoft Team Up on Conversational AI for Doctors’ Offices	Jeff Bauter Engel	10/17/19	Boston
ArsenalBio Launches With $85M for “Programmable” T Cell Therapies	Frank Vinluan	10/17/19	San Francisco
Alexion to Buy Achillion in $930M Marriage of Rare Disease Drug Firms	Frank Vinluan	10/16/19	Boston
Checkmate Pharmaceuticals Names Wooldridge Chief Medical Officer	Frank Vinluan	10/15/19	Boston
Cyteir Adds $40M for Clinical Test of “Synthetically Lethal” Cancer Drug	Frank Vinluan	10/15/19	Boston
Parexel’s Washburn Named Lyra Therapeutics Chief Medical Officer	Frank Vinluan	10/14/19	Boston
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades	Frank Vinluan	10/11/19	Indiana
Vir Bio’s IPO Brings In $143M for Tests of Hepatitis B Drug and More	Frank Vinluan	10/11/19	San Francisco
Bio Roundup: Nobel Prizes, Placebo Effect Rises, ICER’s Fire & More	Alex Lash	10/11/19	National
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma	Frank Vinluan	10/10/19	Boston
The Placebo Effect Is Hobbling New Psychiatric Drugs. What Can Stop It?	Alex Lash	10/10/19	National
Cue Biopharma Promotes Suri to President, Passeri Keeps CEO Role	Frank Vinluan	10/09/19	Boston
Five Years After Y Combinator First Admits Biotechs, They’re Dug In	Bernadette Tansey	10/09/19	San Francisco
Verve Therapeutics Names Lyndra’s Bellinger Chief Scientific Officer	Frank Vinluan	10/08/19	Boston
Catch Duchenne Patient Power, Phil Sharp & More Next Week at The Broad	Ben Fidler	10/08/19	Boston
With $65M, Cygnal Tunes In to Nerve Signals for Drug-Making Clues	Frank Vinluan	10/08/19	Boston
Nobel Prize in Medicine Goes to 3 Who Showed How Cells Sense Oxygen Levels	Frank Vinluan	10/07/19	National
Akcea, Fresh Off C-Suite Shakeup, Dishes Heart Drug to Pfizer for $250M	Ben Fidler	10/07/19	Boston
Unpack Digital Health’s Progress & Pitfalls at X·CON on Oct. 22	Jeff Bauter Engel	10/07/19	Boston
Bio Roundup: PARP Progress, A New Commish, IPO-Palooza & More	Ben Fidler	10/04/19	National
Vertex Pharma Promotes Bozic as Kewalramani’s Successor	Frank Vinluan	10/03/19	Boston
Three Biotechs Raise $320M in IPOs, Two Others Pass on Wall Street	Frank Vinluan	10/03/19	National
Page 1 of 658	next page »

Underwriters and Partners

Xpertise: Watch + Learn

Xconomy Insight · Webinar
The New Era of Emerging Therapies Webinar Series
Potential cures and treatments for diseases are on the horizon for a growing number of patients, thanks to recent breakthroughs in CRISPR gene-editing technologies and in cell and gene therapy.

Sponsored · Whitepaper
Monitoring Solutions for Pharma-CRO/CMO Partnerships to Maintain Quality & Timelines
Implementing electronic solutions for risk mitigation
XiltriX

Sponsored · Whitepaper
Protecting Valuable Life Science Assets & Equipment: Monitoring Solutions
Remain compliant and ensure optimal productivity
XiltriX